Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study

被引:110
作者
Montagnani, A [1 ]
Gonnelli, S [1 ]
Cepollaro, C [1 ]
Pacini, S [1 ]
Campagna, MS [1 ]
Franci, MB [1 ]
Lucani, B [1 ]
Gennari, C [1 ]
机构
[1] Univ Siena, Dept Internal Med, I-53100 Siena, Italy
关键词
bone turnover; bone mineral density; osteoporosis; hypercholesterolemia; statins;
D O I
10.1016/S8756-3282(03)00034-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although several studies have reported a lower risk of osteoporotic fracture in hypercholesterolemic patients treated with statins, so far longitudinal studies on the effects of statins on bone are lacking. The aim of the present study was to evaluate bone mineral density (BMD) and bone turnover changes induced by 1-year simvastatin treatment on postmenopausal women. Thirty consecutive postmenopausal hypercholesterolemic women (61.2 +/- 4.9 years) were treated for 12 months with 40 mg/day simvastatin and 30 normocholesterolemic age-matched postmenopausal women provided control data. In all subjects, at baseline and at 3-month intervals, serum lipids, calcium, phosphate, total and bone alkaline phosphatase (Bone-ALP), and carboxy-terminal fragment of type I collagen (CTx) were measured in a fasting blood sample. At baseline and after 6 and 12 months BMD was measured at lumbar spine (BMD-LS) and at femur (BMD-Ftot) and at femoral neck (BMD-Fn) by DXA. In the simvastatin-treated group Bone-ALP showed a significant increase (P < 0.05) with respect to baseline from the sixth month, whereas serum CTx showed a weak and nonsignificant increase over the study period. In treated women BMD-LS, BMD-Fn, and BMD-Ftot increased respectively by 1.1, 0.9, and 0.4% at Month 6; and by 2.8, 1.0, and 0.8% at Month 12. In controls BMD-LS, BMD-Fn, and BMD-Ftot at the end of the study period decreased by 1.6, 1.4, and 1.2%, respectively. The difference between controls and simvastatin-treated patients was significant (P < 0.05) for both BMD-LS and BMD-Fn only at Month 12. In conclusion our results, although obtained from a small sample of. postmenopausal hypercholesterolemic women, suggest a probable positive effect of simvastatin on bone formation and BMD. (c) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 33 条
[1]  
Bauer DC, 1999, J BONE MINER RES, V14, pS179
[2]   The effect of fluvastatin on parameters of bone remodeling [J].
Bjarnason, NH ;
Riis, BJ ;
Christiansen, C .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (05) :380-384
[3]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[4]   Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J].
Chan, KA ;
Andrade, SE ;
Boles, M ;
Buist, DSM ;
Chase, GA ;
Donahue, JG ;
Goodman, MJ ;
Gurwitz, JH ;
LaCroix, AZ ;
Platt, R .
LANCET, 2000, 355 (9222) :2185-2188
[5]  
Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
[6]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[7]   HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients [J].
Chung, YS ;
Lee, MD ;
Lee, SK ;
Kim, HM ;
Fitzpatrick, LA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1137-1142
[8]  
Coons JC, 2002, ANN PHARMACOTHER, V36, P326
[9]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[10]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645